AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. The company’s non-invasive, sublingual formulation technology is designed to efficiently deliver highly lipophilic drugs with consistent pharmacokinetic profiles. In November of 2018, its lead product candidate DSUVIA™ (sufentanil sublingual tablet 30 mcg) was approved by the U.S. Food and Drug Administration.
AcelRx is committed to meeting the needs of critical access hospitals and rural health providers. We believe DSUVIA can help fill an unmet need in the rural settings, including supporting opioid stewardship, and improving patient care at these facilities.
CONTACTPaul HoweVice President, SalesCell: 913-708-3747Email: email@example.com